Cytotoxic evaluation of fluvastatin and rosuvastatin and effect of fluvastatin in the hela cell cycle

African Journal of Pharmacy and Pharmacology

Volumn 5, Issue 3, 2011, Pages 322-326

  Campos Lara, María ^a   Mendoza Espinoza, José Alberto ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b DEPARTAMENTO DE QUÍMICA   (Mexico)

Author keywords

Cell cycle; Cytotoxicity; Statins

Indexed keywords

FLUINDOSTATIN; ROSUVASTATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; HELA CELL; HUMAN; HUMAN CELL; IC 50; LARYNX CARCINOMA; NASOPHARYNX CARCINOMA; TUMOR CELL LINE;

EID: 79957966592     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: 10.5897/AJPP10.342     Document Type: Article

References (31)

1. Aguilar-Salinas CA, Barrett H, Schonfeld G (1993). Metabolic modes of action of the statins in the hyperlipoproteinemias. Atherosclerosis, 141: 203-207.
2. Anand AV, Chandrasekharan M, Kalavathy S, Uma K, Saravanan MP, Saleem Gani AM, Kumar KV, Senthil R, Kumar PS (2009). The influencing aspects of atorvastatin on C-reactive protein and lipid profile in patients with stroke. Int. J. Biol. Chem., 3: 30-34.
3. Bader T, Fazili J, Madhoum M, Aston C, Hughes D, Rizvi S, Seres K, Hasan M (2008). Fluvastatin inhibits hepatitis C replication in humans. Am. J. Gastroenterol., 103(6): 1383-1389.
4. Bader T, Korba B (2010). Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antiviral. Res., 86(3): 241-245.
5. Buchwald H (1992). Cholesterol inhibition, cancer and chemotherapy. Lancet, 399: 1154-1156.
6. Campos-Lara M, Mendoza-Espinoza JA (2008). Development of a selective extraction method for pravastatin quantification in tablets using HPLC with ultraviolet detection. J. Liq. Chromatogr. R. T., 31(4): 619-623.
7. Chan KWK, Oza MA, Siu LL (2003). The statins as anticancer agents. Clin. Cancer. Res., 9: 10-19.
8. Cooper S (2002). Reappraisal of G1-phase arrest and synchronization by lovastatin. Cell. Biol. Int., 26(8): 715-727.
9. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A (2010). Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res. Treat., 119(1): 137-44.
10. Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, Ghosh-Choudhury G (2010). Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal, 22: 749-758.
11. Glynn SA, O'Sullivan D, Eustace JA, Clynes A, O'Donovan N (2008). The 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer, 1(16): 8-9.
12. Goldstein JL, Brown MS (1990). Regulation of the mevalonate pathway. Nature. 343: 425-430 (1990).
13. Jameson JM, Cruz J, Costanzo A, Terajima M, Ennis FA (2010). A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human gammadelta T lymphocytes. Cell Immunol., 264: 71-77.
14. Kobayashi M, Kagawa T, Takano IS, Hirano T, Iseki K (2007). Effect of medium pH on the cytotoxicity of hydrophilic statins. J. Pharm. Pharmaceut. Sci., 10(3): 332-339.
15. Mahmoud AH (2006). Comparative study between carnosine and fluvastatin in hypercholesterolemic rabbits. J. Applied Sci., 6: 1725-1730.
16. Masuo K, Takeo U, Shinichi K, Kouichi T, Kiyohiro N, Takaaki N, Tadanori M, Hiroyuki O (1998). Cell cycle arrest and antitumor activity of pironetina and its derivate. Cancer Lett., 126: 29-32.
17. Mendoza-Espinoza JA, López-Vallejo F, Fragoso-Serrano M, Pereda-Miranda R, Cerda-García-Rojas CM (2009). Structural reassignment, absolute configuration, and conformation of hypurticin, a highly flexible polyacyloxy-6-heptenyl-5,6-dihydro-2H-pyran-2-one. J. Nat. Prod., 72: 700-708.
18. Milazzo L, Caramma I, Mazzali C, Cesari M, Olivetti M, Galli M, Antinori S (2010). Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. J. Antimicrob. Chemother, 65:735-740.
19. Nunez R (2001). DNA measurement and cell cycle analysis by flow cytometry. Curr. Issues Mol. Biol., 3: 67-70.
20. Osaki T, Hashimoto W, Gambotto A, Okamura H, Robbins PD (1999). Potent antitumour effects mediated by local expression of the mature form of the interferon-g inducing factor, interleukin-18 (IL-18). Gene Ther., 6: 808-815.
21. Patel MR, Patel NJ (2010). In vitro cytotoxicity screening of coumarin compounds on Hep-2 cancer cell line. IJPRonline, 2(1): 88-99.
22. Perchellet JP, Perchellet EM, Crow KR, Buszek KR, Brown N (2009). Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins. Int. J. Mol. Med., 24(5): 633-643.
23. Phadungkit M, Rattarom R, Rattana S (2010). Phytochemical screening, antioxidant, antibacterial and cytotoxic activities of Knema angustifolia_extracts. J. Med. Plant. Res., 4(13): 1269-1272.
24. Philip S, Rista S, Dominic S, Anne M, James M, David V, Jonathan TW, Heidi B, Susan K, Michale RB (1990). New colorimetric cytotoxic assay for anticancer-Drug Screening. J. Nat. Cancer Inst., 82: 1107-1112.
25. Sivacumar R, Alagesaboopathi C (2008). Studies on cytotoxicity and antitumor screening of red and white forms of Abrus precatorius L. Afr. J. Biotechnol., 22: 3984-3988.
26. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112.
27. Takahashi HK, Nishibori M (2007). The antitumor activities of statins. Curr. Oncol., 14(6): 246-247.
28. Takahashi HK, Weitz-Schmidt G, Iwagaki H, Yoshino T, Tanaka N, Nishibori M (2006). Hypothesis: The antitumor activities of statins may be mediated by IL-18. J. Leukoc. Biol., 80(2): 215-216.
29. Wachtershauser A, Akoglu B, Stein J (1992). HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effects of butyrate in the colorectal carcinome cell line Caco-2. Carcinogenesis, 22(7): 1067-1067.
30. Watson VJ, Chambers HS, Smith JP (1987). A pragmatic approach to the analysis of DNA histograms with a definable G1 peak. Cytometry, 8: 1-8.
31. Watts GF, Dimmitt SB (1999). Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr. Opin. Lipidol., 10(6): 561-574.